Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q2 FY2021 Earnings Presentation
13 slides from Angiodynamics's earnings presentation, Jan 7, 2021
Slide 1: Second Quarter 2021 Earnings Presentation
ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments and FY2021 Guidance
Corporate Developments FY2021 Guidance 3 NanoKnife disposable growth was 76% in the U.S. and 30% worldwide. Growth in AngioVac was 24%, and we achieved $2.1 million in Auryon sales. Procedural volumes continued to rebound in the second quarter and reflect less severe declines than the 10-15% decline
Slide 4: Second Quarter FY2021 Highlights
Second Quarter FY2021 Highlights $ in thousands (except per share data) Q2 FY2021 Q2 FY2020 YOY Change Revenue $72,770 $70,003 4.0% Gross Margin 55.2% 59.3% (410 bps) Adjusted EPS $0.01 $0.06 ($0.05) Adjusted EBITDA $5,158 $6,410 ($1,252) Cash Provided by Operations $11,448 $5,937 $5,511 Free Cash F
Slide 5: Second Quarter FY2021 Results (unaudited)
Second Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q2 FY2021 Q2 FY2020 Change YTD FY2021 YTD FY2020 Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $72,770$33,900$23,930$14,940$60,684$12,086 $70,003$31,150$22,784$
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financin
Slide 8: Thrombus Management Portfolio Update
ANGIODYNAMICS Thrombus Management Portfolio Update 8
Slide 9: Deep Vein Thrombosis and Pulmonary Embolism
9 Deep Vein ThrombosisDVT + Pulmonary EmbolismPE = Venous ThromboembolismVTE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply DVT and PE are collectively referred to as VTE 208,0
Slide 10: Thrombus Management: Purpose Built Portfolio & Technology
THROMBUS MANAGEMENTPurpose Built Portfolio & Technology 10 Right Heart AngioVac’s use is currently focused on the Right Heart, which is a $77M addressable market. Pulmonary Embolism Deep Vein Thrombosis A multi-purpose mechanical aspiration device will allow us to compete in the broader DVT & PE add
Slide 11: The Difference: AngioVac System
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient’s own filtered blood to limit procedural blood lo
Slide 12: Planned Portfolio Additions & U.S. Addressable Markets Expansion
THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets Expansion 12 $1.3B $1.6B FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M $3.6B $1.5B 1 2 The planned portfolio additions are not guarantees of future performance
Slide 13: Second Quarter 2021 Earnings Presentation
ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 13